Literature DB >> 7647787

Loss of function effect of RET mutations causing Hirschsprung disease.

B Pasini1, M G Borrello, A Greco, I Bongarzone, Y Luo, P Mondellini, L Alberti, C Miranda, E Arighi, R Bocciardi.   

Abstract

We have introduced three Hirschsprung (HSCR) mutations localized in the tyrosine kinase domain of RET into the RET/PTC2 chimaeric oncogene which is capable of transforming NIH3T3 mouse fibroblasts and of differentiating pC12 rat pheochromocytoma cells. The three HSCR mutations abolished the biological activity of RET/PTC2 in both cell types and significantly decreased its tyrosine phosphorylation. By contrast, a rare polymorphism in exon 18 does not alter the transforming capability of RET/PTC2 or its tyrosine phosphorylation. These data suggest a loss of function effect of HSCR mutations which might act through a dominant negative mechanism. Our model system is therefore capable of discriminating between causative HSCR mutations and rare polymorphisms in the tyrosine kinase domain of RET.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647787     DOI: 10.1038/ng0595-35

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  38 in total

1.  A human model for multigenic inheritance: phenotypic expression in Hirschsprung disease requires both the RET gene and a new 9q31 locus.

Authors:  S Bolk; A Pelet; R M Hofstra; M Angrist; R Salomon; D Croaker; C H Buys; S Lyonnet; A Chakravarti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  Hirschsprung disease, associated syndromes, and genetics: a review.

Authors:  J Amiel; S Lyonnet
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

3.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

Review 4.  [Molecular biology, basic research and diagnosis of Hirschsprung's disease].

Authors:  G Martucciello; O Luinetti; P Romano; U Magrini
Journal:  Pathologe       Date:  2007-03       Impact factor: 1.011

5.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 6.  Genetic basis of Hirschsprung's disease.

Authors:  Paul K H Tam; Mercè Garcia-Barceló
Journal:  Pediatr Surg Int       Date:  2009-06-12       Impact factor: 1.827

Review 7.  Acetylcholine release and the cholinergic genomic locus.

Authors:  M Israël; Y Dunant
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

Review 8.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

9.  Oncological implications of RET gene mutations in Hirschsprung's disease.

Authors:  R H Sijmons; R M Hofstra; F A Wijburg; T P Links; R P Zwierstra; A Vermey; D C Aronson; G Tan-Sindhunata; G J Brouwers-Smalbraak; S M Maas; C H Buys
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

10.  Induction of RET dependent and independent pro-inflammatory programs in human peripheral blood mononuclear cells from Hirschsprung patients.

Authors:  Marta Rusmini; Paola Griseri; Francesca Lantieri; Ivana Matera; Kelly L Hudspeth; Alessandra Roberto; Joanna Mikulak; Stefano Avanzini; Valentina Rossi; Girolamo Mattioli; Vincenzo Jasonni; Roberto Ravazzolo; William J Pavan; Alessio Pini-Prato; Isabella Ceccherini; Domenico Mavilio
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.